Contribute to Human Health

Hanmi devotes to human health to serve corporate social responsibility

Spirit of creation,
Innovation and challenge

We will pioneer a new way and make every endeavor to be an innovative
leading player in global pharmaceutical industry

R&D NO.1

Hanmi makes strenuous and enthusiastic
efforts to develop new treatments for
diabetes, obesity, cancer, autoimmune and rare disease by focusing on R&D

NOTICE

Meet Us at Endocrine Society (ENDO 2023) Meeting

Our Presentation

  • Beneficial effect on intestinal growth of a long-acting GLP-2 analog, HM15912, after treatment switching from conventional GLP-2 drug or other long-acting GLP-2 analogs under clinical development in animal model

    Abstract Number: SAT-028
    Session: P59 - Membrane Receptors and Intracellular Signaling: Membrane Receptor Signaling, June 17, 2023, 1:00 PM - 2:00 PM CST, ENDOExpo

    Presenter: In Young Choi, Ph.D. / Hanmi Pharmaceutical

    Inyoung Choi, Ph.D.
  • HM15912, a novel long-acting GLP-2 analog, improves intestinal growth and absorption capacity in rat model of short bowel syndrome

    Abstract Number: SAT-030
    Session: P59 - Membrane Receptors and Intracellular Signaling: Membrane Receptor Signaling, June 17, 2023, 1:00 PM - 2:00 PM CST, ENDOExpo

    Presenter: Jaehyuk Choi, Ph.D. / Hanmi Pharmaceutical

    Choi, Ph.D.
  • In vitro characterization of a novel long-acting glucagon analog (HM15136) and its potential effect in animal models of chronic hypoglycemic diseases

    Abstract Number: SAT-149
    Session: P65 - Diabetes & Vascular Disease: Hypoglycemia, June 17, 2023, 1:00 PM - 2:00 PM CST, ENDOExpo

    Presenter: Jung Kuk Kim, Ph.D. / Hanmi Pharmaceutical

    Jungkuk Kim, Ph.D.